Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

A risk prediction model was developed and externally validated to estimate the likelihood of subsequent breast cancer in residual breast tissue following an initial ER+ HER2- diagnosis. The model provided valid estimates of 10-year breast cancer risk after a first ER+ HER2- diagnosis, demonstrating its potential for use in counseling patients on bilateral mastectomy.